Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Reborn PMDA Boots Up under New Skipper, Bolstering “Patient First” Initiatives
June 4, 2019
-
BUSINESS Biogen to Leverage Aducanumab Learnings, Spinraza to Remain Foundation of SMA Care: Japan Chief
June 3, 2019
-
REGULATORY June Approval Likely for Chugai’s NTRK-Gene Targeting Entrectinib, 2nd Tumor-Agnostic Drug
May 31, 2019
-
REGULATORY LDP Junior Politicians Set Up Vaccine Study Group
May 31, 2019
-
BUSINESS Japan Drug Firms’ Average Overseas Sales Ratio Nearly 50%, Offshore Biz Remains Way to Go as Home Market Falters: Tally
May 30, 2019
-
REGULATORY Alnylam’s RNAi Drug Now in Line for Japan Approval in June
May 29, 2019
-
TRENDS Female Manager Ratios at Foreign Drug Makers Rising in Japan, 7 Out of 10 Log 20%-Plus
May 28, 2019
-
BUSINESS NEC Ties Up with French Biotech to Develop Neoantigen Vaccines Using AI
May 28, 2019
-
BUSINESS MSD’s Zerbaxa Launch Being Shelved after Foreign Particles Detected
May 27, 2019
-
BUSINESS Big 3 Generic Makers Eke Out Growth in Japan, but Struggle in US; AG Momentum Continues: Jiho Tally
May 24, 2019
-
BUSINESS AbbVie’s Japan Sales in 2018 Double on Maviret Boon
May 23, 2019
-
ACADEMIA Scientific Societies Compile Japan’s First Pharmacotherapy Guidelines for Elderly Cancer Patients
May 23, 2019
-
BUSINESS Japan Pharma Market Shrinks 1.8% in FY2018: IQVIA
May 22, 2019
-
BUSINESS Oncolys Chief Wants Chugai Deal to Accelerate Telomelysin Development in Japan
May 21, 2019
-
BUSINESS Top 4 Wholesalers See Over 1% Operating Margins in FY2018, Thanks Partly to Distribution Improvement Guidelines
May 20, 2019
-
REGULATORY Chugai’s Entrectinib Up for Review for NTRK Tumors on May 30; Label Expansions for Lynparza, Cyramza Also on Agenda
May 17, 2019
-
BUSINESS 21 Japan Drug Makers’ Combined Sales Up 5% in FY2018, but Flagging Japan Biz Continues
May 16, 2019
-
REGULATORY 87% of Drug Makers Say 2018 Pricing Reform Hit Their R&D, Businesses: MHLW Survey
May 15, 2019
-
REGULATORY Kymriah Likely to Fetch 33 Million Yen Price Tag, Collategene to Skip Listing
May 14, 2019
-
BUSINESS 70% of Drug Makers Shave New Grad Hiring, 100-Plus Recruits at Only 3 Firms: Jiho Survey
May 13, 2019
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…